Código QR (código de barras bidimensional)

Unanswered questions on the use of biologics in pediatric asthma

The emergence of biologic therapies for the management of asthma has been a revolutionary change in our capacity to manage this disease.Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can b...

תיאור מלא

שמור ב:
Principais autores: Antonio Nieto, MD, PhD, Zeinab A. El-Sayed, MD, PhD, René Maximiliano Gómez, PhD, Elham Hossny, MD, PhD, Wang Jiu-Yao, MD, DPhil, Ömer Kalayci, MD, Mário Morais-Almeida, Wanda Phipatanakul, MD, Paulo Marcio Pitrez, MD, César Fireth Pozo Beltrán, MD, Paraskevi Xepapadaki, MD, Nikolaos G. Papadopoulos, MD, PhD
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier 2023-11-01
סדרה:World Allergy Organization Journal
נושאים:
Severe childhood asthma
Biologics
Omalizumab
Mepolizumab
Benralizumab
Dupilumab
גישה מקוונת:http://www.sciencedirect.com/science/article/pii/S1939455123000972
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים